MedSci期刊数据库中更新全新citescore

2019-06-08 不详 网络

Elsevier已经悄悄地发布了最新的CiteScore,什么? 你还不知道什么是CiteScore? 好吧,请先大至理解成它是一个三年期影响因子,曾经有一阵很多学者在嚷着要用来替代JCR影响因子。梅斯医学期刊数据库系统中已更新最新的2018年citescore因子,可以直接查询。 先看看这个公布数据中,全世界范围内排名前几十位的期刊,后面我们会大致提一下CiteScore的计算方法等。

Elsevier已经悄悄地发布了最新的CiteScore,什么? 你还不知道什么是CiteScore? 好吧,请先大至理解成它是一个三年期影响因子,曾经有一阵很多学者在嚷着要用来替代JCR影响因子。梅斯医学期刊数据库系统中已更新最新的2018年citescore因子,可以直接查询。

先看看这个公布数据中,全世界范围内排名前几十位的期刊,后面我们会大致提一下CiteScore的计算方法等。

注:以下数据全部来自于Scopus数据库,系人工整理,如有出错,尽请指出,也请谅解,注意以下排名,是在该数据库的Source Type中,选择了Journals排出来的,但有几个期刊小编没见到过。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1738560, encodeId=d2ba1e3856020, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Wed Nov 20 04:21:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561998, encodeId=99c7156199836, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jun 10 13:21:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609813, encodeId=bdc41609813c6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 10 13:21:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367508, encodeId=d91936e508cc, content=好快, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jun 09 15:11:46 CST 2019, time=2019-06-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1738560, encodeId=d2ba1e3856020, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Wed Nov 20 04:21:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561998, encodeId=99c7156199836, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jun 10 13:21:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609813, encodeId=bdc41609813c6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 10 13:21:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367508, encodeId=d91936e508cc, content=好快, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jun 09 15:11:46 CST 2019, time=2019-06-09, status=1, ipAttribution=)]
    2019-06-10 docwu2019
  3. [GetPortalCommentsPageByObjectIdResponse(id=1738560, encodeId=d2ba1e3856020, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Wed Nov 20 04:21:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561998, encodeId=99c7156199836, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jun 10 13:21:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609813, encodeId=bdc41609813c6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 10 13:21:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367508, encodeId=d91936e508cc, content=好快, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jun 09 15:11:46 CST 2019, time=2019-06-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1738560, encodeId=d2ba1e3856020, content=<a href='/topic/show?id=a9dd4e63c4' target=_blank style='color:#2F92EE;'>#CIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4763, encryptionId=a9dd4e63c4, topicName=CIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=eabf34462441, createdName=12498877m109暂无昵称, createdTime=Wed Nov 20 04:21:00 CST 2019, time=2019-11-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1561998, encodeId=99c7156199836, content=<a href='/topic/show?id=309f509e9a' target=_blank style='color:#2F92EE;'>#CORE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5097, encryptionId=309f509e9a, topicName=CORE)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Jun 10 13:21:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1609813, encodeId=bdc41609813c6, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Mon Jun 10 13:21:00 CST 2019, time=2019-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=367508, encodeId=d91936e508cc, content=好快, beContent=null, objectType=article, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c4a5105539, createdName=lovetcm, createdTime=Sun Jun 09 15:11:46 CST 2019, time=2019-06-09, status=1, ipAttribution=)]
    2019-06-09 lovetcm

    好快

    0

相关资讯

CiteScore会成为Scopus的杀手锏吗?期刊排名江山待定

定量的评价指标,这让Scopus 数据库作为科技评价的功能大打折扣。对于科研管理部门来说,不能定量化可不是一件可以接受的事情。 终于,由于 CiteScore 的推出,这种尴尬的局面在2017年到来之前就此结束。十二年磨一剑的 CiteScore ,会成为Scopus 迎战 WOS 的下一个杀手锏吗? 与 

按照新的期刊评价指数CiteScore,柳叶刀竟然没进前200名

出版业巨头Elsevier的CiteScore使用更大的数据库,其对期刊质量的评价结果也与影响因子不同。撰文  Richard Van Noorden科学界最具争议的衡量标准之一现在有了一个崭新的对手。12月8日,出版业巨头Elsevier发布了评估期刊质量的CiteScore指数。尽管CiteScore的排名计算公式在很大程度上模仿了现在最具影响力的期刊影响因子(JIF),但其涵盖

新期刊质量的CiteScore指数挑战影响因子,为时尚早

12月8日,出版业巨头Elsevier发布了评估期刊质量的CiteScore指数(影响因子的重量级对手来了--CiteScore问世)。大家都认为它能挑战大家心目中金标准---影响因子评价体系。CiteScore的排名计算公式在很大程度上模仿了现在最具影响力的期刊影响因子(JIF)体系,做了一些调整 。据梅斯医学最新的分析表明,2015年涵盖的期刊数量达到22209种,是JIF的两倍以上。与201

Medsci可以查询CiteScore啦!

2016年12月8日,学术出版巨头爱思唯尔拿出了自己的期刊影响因子评分系统——CiteScore,该系统一经曝光便被视为传统科研评价体系影响因子JIF的强劲对手。CiteScore与JIF系统相比,有以下特点: (1)期刊涵盖数量众多 (2)影响因子不再按前两年发文数量和引用数量评价,而是三年,覆盖面也更广一些,兼顾了当年影响因子与5年影响因子两个数值的特点 (3